Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics

Won Y. Kim, Hal Broxmeyer, In Seob Han, Doo H. Park, Ki Man Lee, Dass S. Vinay, Byoung S. Kwon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Leukotactin-1 (Lkn-1) is a human CC chemokine that induces chemotaxis of neutrophils, monocytes, eosinophils, and lymphocytes and suppresses colony formation of myeloid progenitor cells in vitro. Present studies evaluated the myeloprotective capabilities of Lkn-1 in vivo against Ara-C and 5-fluorouracil (5-FU). The effect of Lkn-1 on myelopoiesis was first assessed in vivo by injecting recombinant Lkn-1 in C3H/HeJ mice. Lkn-1 rapidly decreased cycling rates and absolute numbers of myeloid progenitor cells in marrow. Lkn-1 administration prior to and during the chemotherapeutics treatment resulted in increased progenitors for colony-forming units-granulocyte/macrophage (CFU-GM), colony-forming units-granulocyte/erythroid/megakaryocyte/macrophage (CFU-GEMM), and burst-forming units-erythroid (BFU-E) compared with a saline-treated group. The protective effects lasted until day 3 after the termination of Ara-C administration and until day 7 after the termination of 5-FU administration. The results indicate that Lkn-1 protects bone marrow myeloid progenitor cells when cytotoxic chemotherapeutics are used in a preclinical setting. These results may be of use in clinical treatment for myeloprotection.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalJournal of Hematotherapy and Stem Cell Research
Volume12
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Myeloid Progenitor Cells
Cytarabine
Fluorouracil
Myelopoiesis
CC Chemokines
Erythroid Precursor Cells
Inbred C3H Mouse
Chemotaxis
Granulocytes
Eosinophils
Bone Marrow Cells
Monocytes
Neutrophils
Stem Cells
Bone Marrow
Macrophages
Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics. / Kim, Won Y.; Broxmeyer, Hal; Han, In Seob; Park, Doo H.; Lee, Ki Man; Vinay, Dass S.; Kwon, Byoung S.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 12, No. 1, 02.2003, p. 107-113.

Research output: Contribution to journalArticle

Kim, Won Y. ; Broxmeyer, Hal ; Han, In Seob ; Park, Doo H. ; Lee, Ki Man ; Vinay, Dass S. ; Kwon, Byoung S. / Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics. In: Journal of Hematotherapy and Stem Cell Research. 2003 ; Vol. 12, No. 1. pp. 107-113.
@article{24decfadd79c4ac9bc254036dd8d4e6f,
title = "Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics",
abstract = "Leukotactin-1 (Lkn-1) is a human CC chemokine that induces chemotaxis of neutrophils, monocytes, eosinophils, and lymphocytes and suppresses colony formation of myeloid progenitor cells in vitro. Present studies evaluated the myeloprotective capabilities of Lkn-1 in vivo against Ara-C and 5-fluorouracil (5-FU). The effect of Lkn-1 on myelopoiesis was first assessed in vivo by injecting recombinant Lkn-1 in C3H/HeJ mice. Lkn-1 rapidly decreased cycling rates and absolute numbers of myeloid progenitor cells in marrow. Lkn-1 administration prior to and during the chemotherapeutics treatment resulted in increased progenitors for colony-forming units-granulocyte/macrophage (CFU-GM), colony-forming units-granulocyte/erythroid/megakaryocyte/macrophage (CFU-GEMM), and burst-forming units-erythroid (BFU-E) compared with a saline-treated group. The protective effects lasted until day 3 after the termination of Ara-C administration and until day 7 after the termination of 5-FU administration. The results indicate that Lkn-1 protects bone marrow myeloid progenitor cells when cytotoxic chemotherapeutics are used in a preclinical setting. These results may be of use in clinical treatment for myeloprotection.",
author = "Kim, {Won Y.} and Hal Broxmeyer and Han, {In Seob} and Park, {Doo H.} and Lee, {Ki Man} and Vinay, {Dass S.} and Kwon, {Byoung S.}",
year = "2003",
month = "2",
doi = "10.1089/152581603321210181",
language = "English",
volume = "12",
pages = "107--113",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics

AU - Kim, Won Y.

AU - Broxmeyer, Hal

AU - Han, In Seob

AU - Park, Doo H.

AU - Lee, Ki Man

AU - Vinay, Dass S.

AU - Kwon, Byoung S.

PY - 2003/2

Y1 - 2003/2

N2 - Leukotactin-1 (Lkn-1) is a human CC chemokine that induces chemotaxis of neutrophils, monocytes, eosinophils, and lymphocytes and suppresses colony formation of myeloid progenitor cells in vitro. Present studies evaluated the myeloprotective capabilities of Lkn-1 in vivo against Ara-C and 5-fluorouracil (5-FU). The effect of Lkn-1 on myelopoiesis was first assessed in vivo by injecting recombinant Lkn-1 in C3H/HeJ mice. Lkn-1 rapidly decreased cycling rates and absolute numbers of myeloid progenitor cells in marrow. Lkn-1 administration prior to and during the chemotherapeutics treatment resulted in increased progenitors for colony-forming units-granulocyte/macrophage (CFU-GM), colony-forming units-granulocyte/erythroid/megakaryocyte/macrophage (CFU-GEMM), and burst-forming units-erythroid (BFU-E) compared with a saline-treated group. The protective effects lasted until day 3 after the termination of Ara-C administration and until day 7 after the termination of 5-FU administration. The results indicate that Lkn-1 protects bone marrow myeloid progenitor cells when cytotoxic chemotherapeutics are used in a preclinical setting. These results may be of use in clinical treatment for myeloprotection.

AB - Leukotactin-1 (Lkn-1) is a human CC chemokine that induces chemotaxis of neutrophils, monocytes, eosinophils, and lymphocytes and suppresses colony formation of myeloid progenitor cells in vitro. Present studies evaluated the myeloprotective capabilities of Lkn-1 in vivo against Ara-C and 5-fluorouracil (5-FU). The effect of Lkn-1 on myelopoiesis was first assessed in vivo by injecting recombinant Lkn-1 in C3H/HeJ mice. Lkn-1 rapidly decreased cycling rates and absolute numbers of myeloid progenitor cells in marrow. Lkn-1 administration prior to and during the chemotherapeutics treatment resulted in increased progenitors for colony-forming units-granulocyte/macrophage (CFU-GM), colony-forming units-granulocyte/erythroid/megakaryocyte/macrophage (CFU-GEMM), and burst-forming units-erythroid (BFU-E) compared with a saline-treated group. The protective effects lasted until day 3 after the termination of Ara-C administration and until day 7 after the termination of 5-FU administration. The results indicate that Lkn-1 protects bone marrow myeloid progenitor cells when cytotoxic chemotherapeutics are used in a preclinical setting. These results may be of use in clinical treatment for myeloprotection.

UR - http://www.scopus.com/inward/record.url?scp=0037294270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037294270&partnerID=8YFLogxK

U2 - 10.1089/152581603321210181

DO - 10.1089/152581603321210181

M3 - Article

C2 - 12662441

AN - SCOPUS:0037294270

VL - 12

SP - 107

EP - 113

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 1

ER -